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ABSTRACT 
Epilepsy is one of the most common neurologic disorders. Underlying cause of epilepsy is unknown in 60 % of 
the patients. Toxoplasma gondii is an intracellular parasite which is capable of forming tissue cysts in brain of 
chronically infected hosts including humans. Some epidemiological studies suggested an association between tox-
oplasmosis and acquisition of epilepsy. In this study we determined seroprevalence of latent Toxoplasma infection 
in a population of Iranian epileptic patients. Participants were classified in three groups as Iranian epileptic patients 
(IEP, n = 414), non-epileptic patients who had other neurologic disorders (NEP, n = 150), and healthy people 
without any neurologic disorders (HP, n = 63). The presence of anti-Toxoplasma IgG antibodies and IgG titer in 
the sera were determined by ELISA method. Anti-T. gondii IgG seroprevalence obtained 35.3 %, 34.7 % and 
38.1 % in IEP, NEP and HP, respectively. The seroprevalence rate was not significantly different among the three 
groups (P = 0.88). Anti-T. gondii IgG titer was 55.7 ± 78, 52.4 ± 74 and 69.7 ± 92 IU/ml in IEP, NEP and HP, 
respectively. There was not any statistically significant difference in the antibody titer between the study groups 
(P = 0.32). The rate of T. gondii infection in epileptic patients was not higher than non-epileptic patients and 
healthy people in the Iranian population.  
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INTRODUCTION 
Epilepsy is the most common neurologi-
cal disorder after stroke and Alzheimer's dis-
ease affecting almost 1 % of people world-
wide (Thurman et al., 2011). In spite of devel-
opment of advanced diagnostic methods, the 
underlying cause of epilepsy is unknown in 
more than 60 % of the patients (Bell et al., 
2014).  
T. gondii is an obligate, intracellular, par-
asitic protozoan that is capable of forming 
cysts in excitable tissues including the brain 
of the host. Nearly two billion of the world 
population have been exposed to T. gondii 
and are seropositive (Subauste, 2012; Weiss 
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and Kim, 2007). T. gondii cysts are micro-
scopic and invisible with MRI or CSF analy-
sis. Tissue cysts seem to persist for the whole 
life of the infected host. Reactivation of the 
parasite in immunocompromised people can 
lead to serious clinical complications includ-
ing encephalitis, myocarditis, severe dissemi-
nated disease and seizures (Ferreira and 
Borges, 2002). 
Recent studies indicated that Toxoplasma 
infection predisposes individuals to neurolog-
ical disorders, particularly psychosis (Fekadu 
et al., 2010). Risk of epilepsy in people with 
toxoplasmosis has also been discussed by 
many researchers (Akyol et al., 2007; Ngugi 
et al., 2013; Palmer, 2007; Yazar et al., 2003). 
However, due to lack of well-matched case-
control studies in large enough population of 
epileptic patients, there is not yet a consensus 
on association between epilepsy and latent 
Toxoplasma infection (Ngoungou et al., 
2015). 
The seroprevalence of latent Toxoplasma 
infection among the general population in 
Iran was found 39.3 % in a recent meta-anal-
ysis study with the range 14-66 % between 
different regions of the country (Daryani et 
al., 2014). Meanwhile, there are two studies 
on the rate of Toxoplasma infection in Iranian 
epileptic patients (Zibaei et al., 2011; 
Allahdin et al., 2015). Zibaei et al. (2011) 
compared the rate of Toxoplasma infection in 
85 epileptic patients with 85 healthy people in 
west of Iran. They reported higher rate of the 
infection in epileptic patients (14.1 %) com-
pared to the healthy people (4.7 %). In con-
trast, results of a study from south of Iran 
(Allahdin et al., 2015) indicated lower 
incidence of Toxoplasma infection in 
epileptic patients than healthy people (14.2 % 
versus 30.4 %). The low sample size, lack of 
aged-matched control group, and conflicting 
results in these two studies led us to conduct 
a study with larger sample size and age-
matched control in the capital of Iran, Tehran, 
to evaluate the frequency and titer of serum 
anti-T. gondii IgG antibody in Iranian epilep-
tic patients.  
The prevalence of an infectious disease in 
a population and the age of that population are 
among most useful data in epidemiological 
studies of the infectious diseases. The annual 
risk of infection (ARI) is a valuable index that 
specifies relationship between age and preva-
lence of disease in a population (Cauthen et 
al., 2002). This index indicates the possibility 
that an individual without previous infection 
has of being infected during the course of a 
year. The other aim of our study was to esti-
mate ARI for toxoplasmosis in our study pop-
ulation.  
 
MATERIALS AND METHODS 
Study population and subject selection  
The study was approved by the ethics 
committee of Pasteur Institute of Iran and 
conforms to Helsinki declaration of 1975 as 
revised in 2000 and 2008. The study 
population is composed of Iranian epileptic 
patients (IEP, n = 414), and non-epileptic 
patients (NEP) suffering from other 
neurologic disorders (n = 150) who referred 
to Loghman hospital (Tehran) throughout the 
country since February 2013 until January 
2015. The age of participants was between 18 
to 64 years. A control age-matched healthy 
people without any neurologic diseases (HP) 
group (n = 63) was also included in the study. 
The inclusion criteria were all adults of age 
18-64 years, with any kind of epilepsy (IEP 
group), or other neurologic disorders except 
for epilepsy (NEP group), or healthy people 
without any neurologic diseases (HP group). 
The exclusion criteria were serum C reactive 
protein more than 10 mg/dL, immunodefi-
ciency, concurrent consumption of immuno-
suppressive drugs, having a history of 
chemotherapy or immunotherapy during last 
6 months, infectious disease, diabetes, 
malnutrition, and HIV. 
The seizure type and etiology of epilepsy 
verified by neurologist Professor Kourosh 
Gharagozli according to the International 
League Against Epilepsy (ILAE) 2001 crite-
ria (Shorvon, 2011).  
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All subjects participated in this study vol-
untarily. Written informed consent was ob-
tained from all subjects following a complete 
description of the study. A 5 mL venous blood 
sample was taken for measuring the titer of 
anti-Toxoplasma antibody. Subject infor-
mation and the data were identified by a code 
to ensure blind analysis. 
 
Serological antibody detection 
Serum of the blood samples were isolated 
and kept at -20° C until use. The presence of 
anti-Toxoplasma IgG antibody in the sera was 
determined using commercial Euroimmun 
ELISA IgG kit (Euroimmun, Lübeck, Ger-
many). The procedure was performed accord-
ing to the manufacturer instruction.  
 
 Statistical analysis  
ARI is calculated by using the following 
equation; ARI = 1-(1-P)1/M, where P is the es-
timated seroprevalence of the infection, and 
M is mean age of intended population 
(Cauthen et al., 2002). SPSS software version 
22.0 (SPSS Inc. Chicago, Illinois) was used to 
analyze the data. The seroprevalence rate 
among the three groups was assessed with the 
two-tailed Pearson’s Chi-Square test. The as-
sociation of T. gondii infection and socio-de-
mographic characteristics was assessed with 
the Pearson’s Chi-Square test, and odds ratio 
(OR) and 95 % confidence interval (CI) were 
calculated. The difference between groups in 
quantitative variables was assessed using one 
way ANOVA. P < 0.05 was considered statis-
tically significant. 
 
RESULTS 
From 802 candidates, 627 people were en-
tered in the study groups including IEP 
(n = 414), NEP (n = 150) and HP (n = 63). 
The seizure type and etiology of epilepsy in 
IEP group were shown in Figure 1. The low-
est and highest frequency of epilepsy be-
longed to provoked and cryptogenic types, re-
spectively. 
 
 
Figure 1: Distribution of epilepsy types in the epi-
leptic population of the study 
 
 
Demographic characteristics of the study 
population are shown in Table 1. The study 
groups were matched by age as 18-30 years, 
31-40 years, 41-50 years and 51 years and 
older. Distribution of male and female sub-
jects in the population was significantly 
(P = 0.014) different in the three groups. The 
results showed that the marriage rate was low 
in the IEP group compared to the NEP and HP 
groups (P = 0.002). In terms of education, the 
population was categorized in three groups; 
school education, high school education and 
university education. The results showed that 
education level is significantly (P < 0.001) 
different between three groups. School educa-
tion was higher in the IEP group while univer-
sity education was higher in the NEP group. 
As Tehran is the capital of Iran, many pa-
tients from other cities might refer to capital 
medical centers. Therefore, we assessed the 
number of capital residents in the study pop-
ulation. As it is seen in Table 1, most of the 
people in the study groups were from Tehran, 
and there was no significant difference be-
tween groups in this regard. 
Table 2 shows the seroprevalence of latent 
T. gondii infection among the study groups. 
The seropositive rate in IEP group was not 
significantly different than that in the NEP 
and HP groups (P = 0.89). Though, the Toxo-
plasma seropositive rate was the 
  
EXCLI Journal 2017;16:256-264 – ISSN 1611-2156 
Received: December 22, 2016, accepted: February 13, 2017, published: March 13, 2017 
 
 
259 
Table 1: Demographic characteristics of the study population 
 IEP (n = 414) NEP (n = 150) HP (n = 63) 95 % CI  (lower - upper) X
2 P 
Mean Age ± SD 32.27 ± 11 32.61 ± 10 33.25 ± 9 31.6 - 33.4  0.776
< 30 24 ± 4 (54.8 %) 25 ± 4 (50.0 %) 25 ± 4 (41.3 %) 23.9 - 24.72 
  
31-40 34 ± 3 (23.2 %) 35 ± 3 (28.7 %) 35 ± 3 (34.9 %) 34.2 - 35.1 
41-50 (%) 46 ± 3 (12.6 %) 46 ± 3 (15.3 %) 45 ± 3 (20.6 %) 44.8 - 46.1 
> 51 56 ± 3 (9.4 %) 55 ± 4 (6.0 %) 52 ± 1 (3.2 %) 55.0 – 56.9 
Gender 
Male 196 (47.3 %) 52 (34.7 %) 23 (36.5 %) 39.2-47.0 
8.5 0.014
Female 218 (52.7 %) 98 (65.3 %) 40 (63.5 %) 53.0-60.8 
Marriage 
Married 210 (50.7 %) 98 (65.3 %) 42 (66.7 %) 52.2-59.5 
12.87 0.002
Single 204 (49.3 %) 52 (34.7 %) 21 (33.3 %) 40.5-47.8 
Education 
  Elementary school 253 (63.1 %) 87 (60.0 %) 34 (53.9 %) 57.7-65.5 
38.47 <0.001High school 89 (22.2 %) 12 (8.3 %) 17 (26.9 %) 17.1-24.5 
University 59 (14.7 %) 46 (31.7 %) 12 (19.0 %) 15.1-21.4 
City of origin 
Tehran 252 (60.9 %) 105 (70.0 %) 43 (68.3 %)  
4.577 0.101
Other cities 162 (39.1 %) 45 (30.0 %) 20 (31.7 %)  
 
Table 2: Seroprevalence of latent T. gondii infection in the epileptic population of the study 
 Sample size Seropositive rate X2 P 
Group 
IEP 414 146 (35.3 %) 0.239 0.888 
NEP 150 52 (34.7 %) 
HP 63 24 (38.1 %) 
Etiology of epilepsy 
Cryptogenic 262 94 (35.9 %) 2.887 0.409 
Symptomatic 88 32 (36.4 %) 
Provoked 26 11 (42.3 %) 
Idiopathic 38 9 (23.7 %) 
IEP: Iranian epileptic patients, NEP: non-epileptic patients suffering from other neurologic 
disorders, HP: healthy individuals without any neurologic diseases 
 
least in idiopathic subgroup (23.7 %) and was 
the most in provoked subgroup (42.3 %), 
there was no significant difference between 
subgroups in this respect (P = 0.41).  
ELISA results showed that anti-T. gondii 
IgG titer were 55.7 ± 78, 52.4 ± 74 and 
69.7 ± 92 IU/ml in the IEP, NEP and HP 
groups, respectively. The difference in the ti-
ter was not significant between groups (one-
way ANOVA, P = 0.32). 
Table 3 demonstrates some socio-demo-
graphic characteristics of the study population 
and the seroprevalence of T. gondii. In our 
study, age was highly associated with the la-
tent infection (P < 0.001). The IgG titer of T. 
gondii also significantly increased (P < 0.001, 
Pearson's r value of + 0.254) with age. The 
IgG titer for ≤ 30, 31-40, 41-50 and ≥ 51 year 
age groups were found as 44.6 ± 76, 
54.4 ± 74, 74.8 ± 77 and 106.3 ± 84, respec-
tively. 
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Table 3: Socio-demographic characteristics and T. gondii seroprevalence in the study population 
Characteristic Number of subjects Tested 
Prevalence of  
T. gondii infection OR (95 % CI) X
2 P 
Age groups (years) 
<30 328 83 (25.3 %) 
 48.91 <0.001
31-40 161 59 (36.6 %) 
41-50 88 46 (52.3 %) 
>51 50 34 (68.0 %) 
Gender      
Male 271 99 (36.5 %) 
0.92 (0.66-1.28) 0.264 0.607 
Female 356 123 (34.6 %) 
Marriage 
Married 350 152 (43.4 %) 
0.44 (0.31-0.63) 22.291 <0.001
Single 277 70 (25.3 %) 
Blood group 
A 132 52 (39.4 %) 
 2.128 0.644 
B 67 22 (32.4 %) 
AB 50 16 (32 %) 
O 164 60 (36.6) 
Education 
Elementary school 374 147 (39.3 %) 
 7.769 0.005 High school 123 38 (30.9 %) 
University 111 29 (26.1 %) 
Eating undercooked 
Yes 129 62 (48.9 %) 
0.46 (0.31-0.69) 14.311 <0.001
No 417 125 (30.0 %) 
Soil contact 
Yes 111 47 (42.3 %) 
0.67 (0.43-1.02) 3.476 0.062 
No 417 137 (32.9 %) 
Visual anomalies 
Yes 216 87 (40.3 %) 
0.68 (0.48-0.98) 4.407 0.036 
No 336 106 (31.5 %) 
Eating out 
Daily 37 11 (29.7 %) 
 6.471 0.167 
Weekly 106 31 (29.2 %) 
Monthly 98 38 (38.8 %) 
Rarely 160 54 (33.7 %) 
Never 62 29 (46.8 %) 
 
 
The total seroprevalence of T. gondii was 
found 0.3541 for study population. It means 
35.4 % of whole population including IEP, 
NEP and HP groups was seropositive.  
The mean age of the population was 32.4 
and ARI was obtained 0.0133.  
Our results showed no correlation be-
tween gender and seropositive rate of T. 
gondii infection (P = 0.61). 
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The married people had mean age of 37.4 
with highly significant titer of T. gondii anti-
bodies (P < 0.001) compared to single people 
(with mean age of 26.1). 
Our results showed that latent T. gondii 
infection was negatively correlated (Pearson 
correlation of -0.112) with high education 
level (P = 0.006).  
Moreover, the results showed that con-
sumption of undercooked meat and raw vege-
tables were highly correlated with Toxo-
plasma infection and considered to be a major 
risk factor (P < 0.001). However, outdoor eat-
ing habit (P = 0.17) or blood group (P = 0.64) 
did not increase the risk of Toxoplasma infec-
tion (Table 3).  
Our results showed that Toxoplasma sero-
positive people had high rate of visual anom-
alies (P = 0.04) compared to uninfected peo-
ple.  
 
DISUSSION 
Results of the present study indicate that 
the seroprevalence of Toxoplasma in Iranian 
epileptic patients was not significantly differ-
ent from non-epileptic patients and healthy 
control people. IgG seroprevalence was 
35.3 %, 34.7 %, and 38.1 % in IEP, NEP, and 
HP, respectively. In term of epilepsy etiology, 
the seroprevalence of Toxoplasma infection 
was not significantly different among the epi-
lepsy subgroups. Although obvious differ-
ence was seen in provoked and idiopathic 
subgroups, the small number of patients in 
these subgroups resulted in non-significant 
difference. 
Numerous studies investigated the associ-
ation between T. gondii infection and epilepsy 
(Akyol et al., 2007; Allahdin et al., 2015; El-
Tantawy et al., 2013; Eraky et al., 2016; 
Ngugi et al., 2013; Stommel et al., 2001; 
Yazar et al., 2003; Zibaei et al., 2011). Some 
of these studies found significant association 
between epilepsy and Toxoplasma infection 
and some did not (Ngoungou et al., 2015). 
Among these studies only one study found 
negative association between toxoplasmosis 
and epilepsy (Allahdin et al., 2015). Most of 
these studies had small sample size except for 
Ngugi et al., (2013) with 2262 subjects (971 
epileptic patients). We also used a large sam-
ple size with 442 epileptic patients. However, 
we did not found any association between ep-
ilepsy and Toxoplasma infection. There are 
two studies, carried out in Iran on the rate of 
T. gondii infection in epileptic patients 
(Allahdin et al., 2015; Zibaei et al., 2011). In 
our study, the seroprevalence of Toxoplasma 
infection was found 35-38 % among epilep-
tic, non-epileptic and control groups. This 
finding is consistent with the recent meta-
analysis study which is reported a 39 % sero-
prevalence of T. gondii in Iranian general 
population (Daryani et al., 2014). However, in 
the two previous studies on the rate of toxo-
plasmosis in Iranian epileptic patients, the se-
roprevalence rate was significantly different 
compared to the finding of the meta-analysis 
study reported by Daryani et al., (2014). 
Zibaei et al. (2011) reported 4.7 % seroposi-
tive rate in healthy people versus 14.1 % in 
epileptic patients. On the other hand, Allaha-
din et al. (2015) found 30.4 % seropositive 
rate in healthy people versus 14.1 % in epilep-
tic patients. Therefore, our results seem to be 
more reliable compared to studies performed 
by Zibaei et al. (2011) and Allahadin et al. 
(2015).  
There are several limitations in the study 
of Zibaei et al. (2011) and Allahadin et al. 
(2015). Zibaei et al. (2011) used a small sam-
ple sizes (85 cases) and only cryptogenic epi-
lepsy cases. Allahdin et al. (2015) used higher 
sample size with 141 epileptic patients. How-
ever, they did not match the age of the study 
groups as the mean age of control cases was 
almost 10 years older than epileptic patients. 
It is well known that the rate of Toxoplasma 
infection is increased with age (Flegr et al., 
2014; Portela et al., 2004). In our study, we 
matched the age of the subjects in the 3 groups 
of the study. In contrast to age, gender is not 
a risk factor for Toxoplasma infection world-
wide (Flegr et al., 2014) and also in Iran 
(Daryani et al., 2014). Therefore, we did not 
match the gender of the groups in our study. 
The other strength of our study might be using 
two control groups i.e. non-epileptic patients 
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that had neurologic disorders other than epi-
lepsy, and healthy people with no disease. A 
positive correlation between Toxoplasma in-
fection and some neurological disease such as 
psychosis has been reported (Fekadu et al., 
2010). Therefore, using a control group of the 
patients with neurologic disorders except for 
epilepsy, will give us a reliable comparison to 
differentiate the correlation of epilepsy (but 
not other neurological disorders) with 
Toxoplasma infection. 
Several mechanisms, mostly obtained 
from animal studies, are postulated for poten-
tial association between toxoplasmosis and 
epilepsy. The most important mechanism is 
coming from high affinity of T. gondii to the 
excitable tissues including nervous system 
where the parasite forms tissue cysts. Recent 
evidence indicates that previous opinion re-
garding the silent status of the parasite in the 
brain is not true; rather T. gondii has a dy-
namic status inside the cysts (Watts et al., 
2015) thereby can change the function of the 
neurons by modulation of some neurotrans-
mitters including GABA (Brooks et al., 
2015), dopamine (Babaie et al., 2017), seroto-
nin (Gatkowska et al., 2013), noradrenaline 
(Gatkowska et al., 2013), nitric oxide (Tonin 
et al., 2014; Dincel and Atmaca 2015), and 
glutamate (Kannan et al., 2016). Moreover, 
serum level of pro-inflammatory cytokines 
also increases during T. gondii infection (Bot-
tari et al., 2015), which contribute to neuropa-
thology of toxoplasmosis. Therefore, modula-
tion of neurotransmitters and cytokine sys-
tems might be involved in the increased sei-
zure susceptibility induced by T. gondii. The 
other main mechanism is the neuronal injury 
caused by the parasite. The injury is triggered 
either directly by rupture of the cysts, or indi-
rectly by activation of the immune system and 
subsequent inflammation and tissue necrosis. 
Therefore, both immune response to the para-
site invasion and altered neurotransmission 
by parasite itself can contribute to the devel-
opment of epilepsy by toxoplasmosis. 
There is some evidence that some antiepi-
leptic drugs are able to inhibit T. gondii para-
site. For instance, valproic acid, which is a 
broad-spectrum anticonvulsant drug effi-
ciently inhibits Toxoplasma growth in vitro 
(Jones-Brando et al., 2003). In addition car-
bamazepine, another anticonvulsant medica-
tion, had some effects on T. gondii growth 
(Jones-Brando et al., 2003). Therefore, it is 
possible that the use of antiepileptic drugs 
might inhibit the activity of the parasite and 
affects seropositive rate of T. gondii in epilep-
tic patients. Furthermore, many of epileptic 
patients start taking antiepileptic drugs from 
an early age that may protect them against T. 
gondii infection.  
We found that the prevalence of anti-tox-
oplasma antibodies significantly increased 
with age, which is in agreement with the re-
sults of other researchers (Bobic et al., 1998; 
Daryani et al., 2014; Ertug et al., 2005; Jones 
et al., 2001; Kamani et al., 2009). Since diet 
changes with age, eating the raw or semi-
cooked meat in adulthood increases the risk of 
exposure to the parasite. Thus, the prevalence 
of infection in adults is expected to be higher 
than that in children. On the other hand, con-
sistent with other studies (Jones et al., 2001), 
we found that low level of education is asso-
ciated with the increased risk of infection with 
T. gondii. The knowledge on and the adher-
ence to hygiene guidelines in the educated 
people are more than uneducated people. 
Most of educated people are well aware the 
modes of transmission of toxoplasmosis and 
therefore, are less prone to Toxoplasma infec-
tion. Hence, it is important that populations 
with high risk of infection are educated re-
garding the modes of transmission of toxo-
plasmosis and tips to prevent the spread of 
disease. 
The annual risk of toxoplasmosis in the 
population of our study was estimated 
1.33 %. This value reflects the probability 
that an individual without previous contact 
with T. gondii might acquire toxoplasmosis 
during the course of a year. ARI value is re-
ported for some infectious diseases such as tu-
berculosis. However, we did not find any 
study reporting ARI for toxoplasmosis. Ra-
ther the prevalence is usually reported for tox-
oplasmosis. Therefore, we could not compare 
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the ARI value obtained in our study with other 
similar studies. However, we found a 35-
38 % seroprevalence for Toxoplasma infec-
tion in our study population, which is similar 
to the seroprevalence of T. gondii in Iranian 
general population reported in a recent meta-
analysis study (Daryani et al., 2014) . 
In our study, Toxoplasma seropositive 
people had high rate of visual anomalies. This 
finding is in line with the finding of other sim-
ilar studies (Saadatnia and Golkar, 2012). It is 
shown that the most common finding in ac-
quired, congenital and reactivated toxoplas-
mosis is ophthalmic infections such as retino-
choroiditis, which leads to severe ocular ab-
normalities and even blindness (Weiss and 
Kim, 2007).  
In conclusion, the rate of T. gondii infec-
tion in a population of Iranian epileptic pa-
tients was not higher than that of correspond-
ing non-epileptic patients and healthy non-ep-
ileptic people. Prospective studies with large 
sample size in clinical subgroups of epileptic 
patients with well-matched control groups 
across the country are suggested to more clar-
ify the impact of T. gondii on acquisition of 
epilepsy. 
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